Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 6.25 GBp
Change Today 0.00 / 0.00%
Volume 302.7K
OXP On Other Exchanges
As of 11:35 AM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

oxford pharmascience group p (OXP) Snapshot

6.25 GBp
Previous Close
6.25 GBp
Day High
6.25 GBp
Day Low
6.25 GBp
52 Week High
06/22/15 - 13.50 GBp
52 Week Low
12/10/14 - 3.23 GBp
Market Cap
Average Volume 10 Days
-0.0032 GBp
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

oxford pharmascience group p (OXP) Related Businessweek News

No Related Businessweek News Found

oxford pharmascience group p (OXP) Details

Oxford Pharmascience Group Plc, a specialty pharmaceutical company, develops and commercializes drugs from its proprietary technology platform primarily in the United Kingdom, Brazil, and the Middle East. Its prescription and OTC medicines focus on pain relief and cardiovascular disease indications. The company’s product pipeline includes programs in non-steroidal anti-inflammatory drugs comprising ibuprofen, naproxen, diclofenac, and aspirin, as well as statins, such as atorvastatin. It also provides calcium/vitamin D chews that taste better and dissolve faster. The company was formerly known as Oxford Nutrascience Group Plc and changed its name to Oxford Pharmascience Group Plc in May 2011. Oxford Pharmascience Group Plc was founded in 2008 and is based in London, the United Kingdom.

11 Employees
Last Reported Date: 03/4/15
Founded in 2008

oxford pharmascience group p (OXP) Top Compensated Officers

Founder, Chief Executive Officer and Director
Total Annual Compensation: 108.0K GBP
Chief Financial Officer, Company Secretary an...
Total Annual Compensation: 81.0K GBP
Compensation as of Fiscal Year 2014.

oxford pharmascience group p (OXP) Key Developments

Oxford Pharmascience Group Plc Reports Un-Audited Consolidated Earnings Results for the Six Months Ended June 30, 2015

Oxford Pharmascience Group Plc reported un-audited consolidated earnings results for the six months ended June 30, 2015. For the six months, the company reported revenue of £342,000 compared to £336,000, operating loss of £2,168,000 compared to £1,729,000, loss before tax of £2,159,000 compared to £1,729,000, loss after tax attributable to equity holders of the parent of £2,159,000 or 0.21 pence per diluted share compared to £1,729,000 or 0.17 pence per diluted share and net cash outflow from operations of £2,038,000 compared to £1,883,000 for the last year.

Oxford Pharmascience Group Plc to Report First Half, 2015 Results on Sep 22, 2015

Oxford Pharmascience Group Plc announced that they will report first half, 2015 results on Sep 22, 2015

Oxford Pharmascience Announces Results of its Proof of Concept Clinical Study

Oxford Pharmascience announced the results of its proof of concept clinical study to determine the extent of upper gastrointestinal (GI) tract irritation of its OXPzeroTM 250mg tablet compared with the Naprosyn® 250mg tablet by endoscopic evaluation. The primary endpoints of the study were 1. a comparison of the overall Lanza score and 2. a comparison of the total number of erosions observed in the stomach and duodenum. In the study both OXP005 and Naprosyn® exhibited a similar Lanza score while OXP005 exhibits a moderate (c. 26%) reduction in total erosions, albeit at a non statistically significant level. OXP005 meets the primary endpoint of reduced erosions exhibiting a major (c. 38%) reduction of total erosions which is statistically significant after accounting for ineligible subjects. While OXP005 is reducing the number of erosions, the Lanza score endpoint was not met. The company plans to begin partnering discussions in the coming months with opportunities evaluated on the basis of both current and anticipated data, with the aim of achieving the optimal commercial outcome and value for shareholders. The company's strong balance sheet provides greater commercial flexibility as it enters these discussions, including to conduct further work to adapt the platform for naproxen.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OXP:LN 6.25 GBp 0.00

OXP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OXP.
View Industry Companies

Industry Analysis


Industry Average

Valuation OXP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 88.3x
Price/Book 3.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 105.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OXFORD PHARMASCIENCE GROUP P, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at